Suppr超能文献

棕色脂肪组织影响格雷夫斯病治疗期间脂联素和甲状腺激素的变化。

Brown adipose tissue influences adiponectin and thyroid hormone changes during Graves' disease therapy.

机构信息

Lee Kong Chian School of Medicine, Nanyang Technological University (NTU), Singapore, Singapore.

Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A *STAR), Singapore.

出版信息

Adipocyte. 2022 Dec;11(1):389-400. doi: 10.1080/21623945.2022.2104509.

Abstract

Thyroid hormones (TH), adiponectin and brown adipose tissue (BAT) are regulators of energy homoeostasis. Influence of BAT activity on the relationship between TH and adiponectin remains unexplored. The aim of the study was to identify the relationship between TH and adiponectin and to clarify the impact of active BAT on the metabolic effects of adiponectin before and after the correction of thyrotoxicosis. Twenty-one patients with newly diagnosed hyperthyroidism from Graves' disease were recruited. A titration dosing regimen of thionamide anti-thyroid drug (ATD) was used to establish euthyroidism over 12-24 weeks. Anthropometric, biochemical and adipocytokine parameters were measured before and after control of hyperthyroidism. BAT activity was quantified by fusion 18 F-fluorodeoxyglucose (18 F-FDG) PET/MR imaging, and patients were grouped based on BAT status. Plasma adiponectin level was significantly increased following correction of hyperthyroidism in the overall sample. Free thyroxine (FT4) was also identified as a predictor of adiponectin level in thyroid dysfunction. However, significant changes in adiponectin level and correlations involving adiponectin were absent in BAT-positive patients but maintained in BAT-negative patients. BAT activity diminishes the correlative relationship with body composition and abolishes TH and adiponectin relationships when transitioning from a hyperthyroid to euthyroid state.

摘要

甲状腺激素(TH)、脂联素和棕色脂肪组织(BAT)是能量稳态的调节剂。BAT 活性对 TH 和脂联素之间关系的影响仍未得到探索。本研究的目的是确定 TH 和脂联素之间的关系,并阐明在纠正甲状腺功能亢进前后,活跃的 BAT 对脂联素代谢作用的影响。招募了 21 名来自格雷夫斯病的新诊断为甲状腺功能亢进的患者。使用硫脲类抗甲状腺药物(ATD)滴定剂量方案在 12-24 周内建立甲状腺功能正常。在控制甲状腺功能亢进之前和之后测量了人体测量、生化和脂肪细胞因子参数。通过融合 18F-氟脱氧葡萄糖(18F-FDG)PET/MR 成像来定量 BAT 活性,并根据 BAT 状态对患者进行分组。在整个样本中,甲状腺功能亢进得到纠正后,血浆脂联素水平显著升高。游离甲状腺素(FT4)也被确定为甲状腺功能障碍时脂联素水平的预测因子。然而,在 BAT 阳性患者中,脂联素水平的显著变化以及涉及脂联素的相关性并不存在,但在 BAT 阴性患者中仍存在。当从甲状腺功能亢进过渡到甲状腺功能正常状态时,BAT 活性会降低与身体成分的相关性,并消除 TH 和脂联素之间的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca8/9336474/1a116c36f942/KADI_A_2104509_F0001_B.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验